Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Sunil Sharma; Raoul Tibes; Bruno Bastos; Mitesh Borad; Bryan Wong; Ernesto Wasserman; Cristian Fernandez; Takumi Kawabe; Daniel Von Hoff; Geoffrey I. Shapiro

doi:10.1158/1535-7163.TARG-09-B47

Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Sunil Sharma, Raoul Tibes, Bruno Bastos, Mitesh Borad, Bryan Wong, Ernesto Wasserman, Cristian Fernandez, Takumi Kawabe, Daniel Von Hoff, Geoffrey I. Shapiro

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Molecular Cancer Therapeutics
Volume	8
DOIs	https://doi.org/10.1158/1535-7163.TARG-09-B47
State	Published - Dec 10 2009

Disciplines

Gastroenterology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1158/1535-7163.TARG-09-B47License: Unspecified

Cite this

@article{1f76b38bcad54bd6a89e21819c8f6cdf,

title = "Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies",

author = "Sunil Sharma and Raoul Tibes and Bruno Bastos and Mitesh Borad and Bryan Wong and Ernesto Wasserman and Cristian Fernandez and Takumi Kawabe and \{Von Hoff\}, Daniel and Shapiro, \{Geoffrey I.\}",

note = "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA Background: CBP501 is a synthetic peptide that appears to increase intracellular CDDP and enhance DNA damage caused by bleomycin and CDDP in cancer cells, which may lead to cell death. Activity has been identified in various tumor models.",

year = "2009",

month = dec,

day = "10",

doi = "10.1158/1535-7163.TARG-09-B47",

language = "American English",

volume = "8",

journal = "Molecular Cancer Therapeutics",

}

TY - JOUR

T1 - Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

AU - Sharma, Sunil

AU - Tibes, Raoul

AU - Bastos, Bruno

AU - Borad, Mitesh

AU - Wong, Bryan

AU - Wasserman, Ernesto

AU - Fernandez, Cristian

AU - Kawabe, Takumi

AU - Von Hoff, Daniel

AU - Shapiro, Geoffrey I.

N1 - Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA Background: CBP501 is a synthetic peptide that appears to increase intracellular CDDP and enhance DNA damage caused by bleomycin and CDDP in cancer cells, which may lead to cell death. Activity has been identified in various tumor models.

PY - 2009/12/10

Y1 - 2009/12/10

UR - https://mct.aacrjournals.org/content/8/12_Supplement/B47

U2 - 10.1158/1535-7163.TARG-09-B47

DO - 10.1158/1535-7163.TARG-09-B47

M3 - Article

VL - 8

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

ER -

Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) ‐ results of two phase I/II studies

Disciplines

Access to Document

Other files and links

Cite this